Home » Stocks » TNXP

Tonix Pharmaceuticals Holding Corp. (TNXP)

Stock Price: $0.910 USD -0.046 (-4.85%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $0.910 0.000 (-0.01%) Jan 15, 7:59 PM
Market Cap 240.95M
Revenue (ttm) n/a
Net Income (ttm) -46.33M
Shares Out 127.20M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $0.910
Previous Close $0.956
Change ($) -0.046
Change (%) -4.85%
Day's Open 0.930
Day's Range 0.880 - 0.950
Day's Volume 30,253,420
52-Week Range 0.404 - 1.730

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021

GlobeNewsWire - 2 days ago

CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the...

GlobeNewsWire - 5 days ago

CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it ...

GlobeNewsWire - 1 week ago

CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Set...

Benzinga - 3 weeks ago

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penn...

Other stocks mentioned: BIOL, JAGX, SENS
GlobeNewsWire - 3 weeks ago

Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19

GlobeNewsWire - 3 weeks ago

University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromes University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromes

InvestorPlace - 1 month ago

Tonix Pharmaceuticals (TNXP) news for Monday includes results from a recent Phase 3 clinical trial boosting TNXP stock higher. The post Tonix Pharmaceuticals News: TNXP Stock Soars on Fibromya...

Bloomberg Markets and Finance - 1 month ago

Covid-19 Is Not Going to Go Away: Tonix Pharmaceuticals CEO

Dec.06 -- Seth Lederman, chairman and chief executive officer of Tonix Pharmaceuticals, talks about the coronavirus outbreak and the rollout of vaccines. Tonix has two Covid-19 vaccine in the ...

GlobeNewsWire - 2 months ago

Anti-SARS-CoV-2 Neutralizing Antibodies Elicited in All Eight TNX-1800 Vaccinated Animals

GlobeNewsWire - 2 months ago

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time

InvestorPlace - 2 months ago

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...

Other stocks mentioned: CANF, FPRX, GTBP, IFRX, VTVT, VXRT
GlobeNewsWire - 2 months ago

CHATHAM, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Set...

GlobeNewsWire - 2 months ago

CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Set...

GlobeNewsWire - 2 months ago

Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020

GlobeNewsWire - 3 months ago

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

GlobeNewsWire - 3 months ago

CHATHAM, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Set...

GlobeNewsWire - 3 months ago

Topline Results of Full Study Expected Fourth Quarter 2020

GlobeNewsWire - 3 months ago

Facility Addresses the Shortage of Vaccine Production Capacity in the U.S.

GlobeNewsWire - 3 months ago

Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020

GlobeNewsWire - 4 months ago

Results from COV-LOGIC Study Expected in First Half of 2021 Results from COV-LOGIC Study Expected in First Half of 2021

GlobeNewsWire - 4 months ago

Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive ...

GlobeNewsWire - 5 months ago

Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Fo...

InvestorPlace - 5 months ago

Penny stocks will always be risky. That said, with the huge disconnect we’re seeing in the markets, now may be a time to gamble.

Other stocks mentioned: IDEX, SOLO, TDRYD, XSPA, ZOM
GlobeNewsWire - 5 months ago

NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it has regain...

GuruFocus - 5 months ago

Their share prices are predicted to bounce back strongly

Other stocks mentioned: CLSK
GlobeNewsWire - 5 months ago

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is ...

24/7 Wall Street - 5 months ago

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID...

Other stocks mentioned: ACAD, CTSO, GNW, HIBB, IBM, LLNW, NBEV, QIWI
GlobeNewsWire - 6 months ago

Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics

GlobeNewsWire - 6 months ago

NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the clo...

GlobeNewsWire - 6 months ago

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has ...

GlobeNewsWire - 6 months ago

Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Against COVID-19 Based on Bovine Parainfluenza Virus

GlobeNewsWire - 6 months ago

Target Enrollment Completed Ahead of Schedule

GlobeNewsWire - 6 months ago

Tonix's Advanced Development Center Will House Laboratories Dedicated to Process and Analytical Development

GlobeNewsWire - 6 months ago

Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected Enrollment

GlobeNewsWire - 6 months ago

TNX-1700 (Stabilized Recombinant Trefoil Factor 2) (rTFF2-CTP) Enhances Anti-tumor Activity of PD-1 blockade in Mouse Models of Colorectal Cancer

GlobeNewsWire - 6 months ago

Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19

GlobeNewsWire - 6 months ago

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that precli...

GlobeNewsWire - 7 months ago

TNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial Pain TNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial Pain

GlobeNewsWire - 7 months ago

NEW YORK, June 10, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appoint...

GlobeNewsWire - 7 months ago

Collaboration includes Development of Manufacturing Processes and to Supply Clinical Trial Material to Support Tonix’s Development of TNX-1800 Collaboration includes Development of Manufacturi...

GlobeNewsWire - 7 months ago

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, posted two posters for the A...

GlobeNewsWire - 7 months ago

NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointm...

GlobeNewsWire - 8 months ago

Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform

GlobeNewsWire - 8 months ago

Enrollment Continues in Phase 3 RELIEF Study, with Interim Results of the First 50 Percent of Participants Expected in September 2020

GlobeNewsWire - 8 months ago

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive...

GlobeNewsWire - 10 months ago

NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the cl...

GlobeNewsWire - 10 months ago

NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered ...

About TNXP

Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vacc... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Seth Lederman
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
TNXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for TNXP stock is "Strong Buy" and the 12-month stock price forecast is 3.25.

Price Target
$3.25
Analyst Consensus: Strong Buy